Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 10 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2024 According to an ASLAN Pharmaceuticals media release, company will today host a virtual KOL event , during which Company management will present new data from the interim analysis of the Phase 2 TREK-DX study at 8:00 am ET.
30 Apr 2024 According to an ASLAN Pharmaceuticals media release, the company management will present new data from the interim analysis of this study
22 Apr 2024 According to an ASLAN Pharmaceuticals media release, the interim data will be submitted for presentation at an upcoming scientific conference.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com